Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenebrutinib versus ocrelizumab in adults with primary progressive multiple sclerosis
MOH_2020-10-18_009409Phase 3Recruiting
- Sponsor
- Roche
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fenebrutinib and ocrelizumab in primary progressive multiple sclerosis (PPMS) (2 arms), sponsored by Roche. Started Oct 2020; status: recruiting.
02
Drugs
fenebrutinibocrelizumab
03
Conditions
primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on MOH_2020-10-18_009409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-10-18_009409.